Lv11
70 积分 2025-08-15 加入
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
2天前
已完结
Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy
2天前
已完结
Antibody–Drug Conjugates: A Comprehensive Review
25天前
已完结
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
2个月前
已完结
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
2个月前
已完结
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
2个月前
已完结
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
3个月前
已完结
GPX3 promotes cisplatin resistance in TNBC by manipulating ROS-TGFB1-ZEB2
4个月前
已完结
GPX3 expression was down-regulated but positively correlated with poor outcome in human cancers
4个月前
已完结
State of art of advanced triple negative breast cancer
5个月前
已完结
皖公网安备34019202002308
